The Metabolic Clinical Research Unit (MRCU) and the Phenotyping Laboratory opened in January 2007 and are the primary sites where this research is conducted. The MCRU is comprised of ten private inpatient rooms modified to accommodate the needs and safety of patients with extreme obesity (class III). See http://www2.niddk.nih.gov/Research/ClinicalResearch/MCRU/. As part of this natural history study, baseline phenotypic data is obtained in subjects of normal weight, overweight and class I, II and III obesity. Participants are provided a summary of clinically useful results that they can share with their physicians in planning weight loss strategies and are invited to return for yearly evaluations. Validation studies to assess the dynamic range and reproducibility of the equipment including the cart and room calorimeters, DEXA and ADP and exercise equipment have been performed. A bank of skeletal muscle, fat and peripheral blood for genomic DNA is being created on the extensively phenotyped subjects and is shared with investigators across the NIH campus. Subject accrual to target inclusion of patients with genotypes associated with weight dysregulation or metabolic disturbance has begun. Subjects participating in weight loss interventions such as bariatric surgery are targeted for follow-up studies to assess changes in body composition and energy expenditure. A collaboration with the NCI Nutritional Epidemiology Branch aims to validate new tools for studying self report of exercise and food intake.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2014
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Muniyappa, Ranganath; Noureldin, Radwa A; Abd-Elmoniem, Khaled Z et al. (2018) Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals. Cardiorenal Med 8:140-150
Muniyappa, Ranganath; Abel, Brent S; Asthana, Asha et al. (2017) Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. J Clin Lipidol 11:543-550
Glicksman, Michael; Asthana, Asha; Abel, Brent S et al. (2017) Plasma serpinB1 is related to insulin sensitivity but not pancreatic ?-Cell function in non-diabetic adults. Physiol Rep 5:
Kerns, Jennifer C; Guo, Juen; Fothergill, Erin et al. (2017) Increased Physical Activity Associated with Less Weight Regain Six Years After ""The Biggest Loser"" Competition. Obesity (Silver Spring) 25:1838-1843
Abel, Brent S; Muniyappa, Ranganath; Stratton, Pamela et al. (2016) Effects of Recombinant Human Leptin (Metreleptin) on Nocturnal Luteinizing Hormone Secretion in Lipodystrophy Patients. Neuroendocrinology 103:402-7
Stolze, Brian R; Gounden, Verena; Gu, Jianghong et al. (2016) An improved micro-method for the measurement of steroid profiles by APPI-LC-MS/MS and its use in assessing diurnal effects on steroid concentrations and optimizing the diagnosis and treatment of adrenal insufficiency and CAH. J Steroid Biochem Mol Biol 162:110-6
Kassai, Andrea; Muniyappa, Ranganath; Levenson, Amy E et al. (2016) Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. J Clin Endocrinol Metab 101:1790-7
Ma, Xinran; Xu, Lingyan; Alberobello, Anna Teresa et al. (2015) Celastrol Protects against Obesity and Metabolic Dysfunction through Activation of a HSF1-PGC1? Transcriptional Axis. Cell Metab :
Lizunov, Vladimir A; Stenkula, Karin G; Blank, Paul S et al. (2015) Human adipose cells in vitro are either refractory or responsive to insulin, reflecting host metabolic state. PLoS One 10:e0119291
Sasai, Hiroyuki; Brychta, Robert J; Wood, Rachel P et al. (2015) Does Visceral Fat Estimated by Dual-Energy X-ray Absorptiometry Independently Predict Cardiometabolic Risks in Adults? J Diabetes Sci Technol 9:917-24

Showing the most recent 10 out of 23 publications